利塞膦酸钠治疗绝经后骨质疏松症患者血清IL-6、TNF-α的变化

Changes of interleukin-6,tumor necrosis factor alpha on the pathogenesis of postmenopausal osteoporosis after administration of risedronate

目的探讨白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)在利塞膦酸钠治疗绝经后骨质疏松症中变化的意义。方法根据骨密度(BMD)检查结果,选择46例绝经后骨量减少和骨质疏松妇女,采用放免法测定治疗前后血清IL-6、TNF-α、骨钙素(BGP),ELASA法测I型胶原交联氨基末端肽(NTX)。结果绝经后骨质疏松妇女应用利塞膦酸钠5mg/d治疗1年后,与治疗前相比血清IL-6、TNF-α水平下降,血清BGP水平及尿NTX/尿肌酐(Cr)水平降低,BMP上升。对照组治疗后,上述指标无明显改变。两组治疗后相比,上述指标差异有显著性。结论利塞膦酸钠治疗骨质疏松症可能部分是通过抑制IL-6、TNF-α的产生而发挥作用的。

Objective To investigate the effect of interleukin-6 （IL-6） and tumor necrosis factor alpha（TNF-α） on the pathogenesis of postmenopausal osteoporosis （PMOP） after administration of risedronate. Methods According to the result of bone mineral density（BMD） ,46 PMOP and osteopenia women were selected. Before and after treatment, serum levels of IL-6,TNF-α ,BGP were detected by radioimmunoassay method, and urineN-terminal telopeptide of type I collagen （NTX） by ELASA method. Results In residronate group, serum levels of IL-6, TNF-α, BGP and the ratio of urine NTX/Cr were decreased and BMD were increased after treatment. Compared with control group there were significiant differences, while the control group had no significiant differece after treatment. Conclusion Risedronate prevents bone loss in PMOP, and its mechanisms is at least in part inhibiting IL-6 and TNF-α production.